Objective: To investigate the expressions and clinicopathologic significance of Id2 and NF-κB/P65 in gastric cancer. Methods: Immunohistochemistry was used to detect Id2 and NF-κB/P65 expressions in gastric cancer tissues of 336 cases and paraneoplastic normal mucosa tissues of 60 cases.The expressions of Id2 and NF-κB/P65 in gastric cancer were significantly higher than those in normal mucosa tissues (χ(2)=44.631, P<0.001; χ(2)=34.650, P<0.001). Results: The positive expression rates of Id2 and NF-κB/P65 were 71.4% (240/336) and 56.3% (189/336) in cancer tissues, and 26.7%(16/60) and 15.0%(9/60)in normal tissues, respectively.Id2 and NF-κB/P65 were all related to tumor size, differentiation degree, infiltrative depth, lymphatic invasion, distant metastasis and clinical TNM stage (P<0.05). The 5-year survival rate of the patients with Id2 or NF-κB/P65 expression was lower than that of patients with negative Id2 or NF-κB/P65 expression (χ(2)=52.329, P<0.001; χ(2)=20.525, P<0.001). Id2 expression in gastric cancer was positively correlated with the NF-κB/P65 expression (r=0.292, P<0.001). And the NF-κB/P65 expression in the Id2 positive group is significantly higher than that in the group with negative Id2 (χ(2)=28.681, P<0.001). The final multivariate Cox regression model indicated that Id2 expression was an independent prognostic factor for overall survival after operation (HR=2.327, 95%CI 1.622-3.337, P<0.001). Conclusions: Id2 and NF-κB/P65 may synergistically promote the generation and evolution of gastric cancer, and their co-detection can be of great importance for clinical assessment of tumor biological behavior and prognosis in patients with gastric cancer.
目的： 研究DNA结合抑制因子2(Id2)和核转录因子κB(NF－κB)/P65在胃癌中的表达并探讨其与临床病理因素及患者术后生存时间的关系。 方法： 采用PV6000二步法检测有完整随访资料的336例胃癌及60例癌旁组织中Id2和NF－κB/P65的表达情况。 结果： 胃癌中Id2在胃癌组织中的阳性率为71.4%(240/336)，癌旁组织中的阳性率为26.7%(16/60)；NF－κB/P65在胃癌组织中的阳性率为56.3%(189/336)，癌旁组织中的阳性率为15.0%( 9/60)；Id2和NF－κB/P65在胃癌组织中的表达均显著高于在癌旁组织中的表达(χ(2)＝44.631，P<0.001；χ(2)＝34.650，P<0.001)。Id2与NF－κB/P65的表达均与肿瘤大小、分化程度、浸润深度、淋巴结转移、TNM分期和出现腹腔及远处转移相关(P<0.05); Id2和NF－κB/P65阳性表达组患者的5年生存率均低于阴性表达组(χ(2)＝52.329，P<0.001；χ(2)＝20.525，P<0.001)。Id2和NF－κB/P65在胃癌中的表达呈正相关(r＝0.292，P<0.001)；NF－κB/P65在Id2阳性组中的表达显著高于在Id2阴性组中的表达(χ(2)＝28.681，P<0.001)。Cox风险比例模型显示，Id2是患者术后总体生存时间的独立预后因子(HR＝2.327，95%CI 1.622～3.337，P<0.001)。 结论： Id2和NF－κB/P65在胃癌的发生发展、转移中存在协同促进作用，可考虑作为胃癌临床评价肿瘤生物学行为及评估预后的有用指标。.
Keywords: Biological markers; Immunohistochemistry; Prognosis; Stomach neoplasms.